|
Accueil > Actualité
Valbiotis: 'broad success' of phase II/III study
(CercleFinance.com) - Valbiotis announces the broad success of a Phase II/III study on Lipridriveâ (the active ingredient in Valbiotisâ Pro Cholestérol).
Carried out on 180 subjects with mild to moderate hypercholesterolemia, this international, multicenter, randomized, placebo-controlled study validated the efficacy of Lipridriveâ at a dose of 5 g per day on the primary endpoint of lowering LDL cholesterol after 3 months of supplementation. On completion of all analyses, the full results of the HEART II study will be submitted for presentation at international congresses and in international peer-reviewed journals. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
30/05/2025 18:02
GE HealthCarede nouvelles directives recommandent Cerianna 30/05/2025 17:37 Aker Solutionscontrat de 2 GW pour BalWin2 en Allemagne 30/05/2025 17:08 Netflixle titre surperforme, BofA en renfort 30/05/2025 16:35 Pfizerla mortalité d'un cancer colorectal divisée par deux 30/05/2025 16:24 Alstomextension de la ligne 1 du métro de Kanpur, en Inde 30/05/2025 16:05 Solariasoutenu par un relèvement de broker Tous les articles sociétés |
